Sinolink Securities gave shengnuobiotechnology an overweight rating, with R&D advancement, production capacity expansion, and promising growth in the peptide field.

Sinolink Securities gave shengnuobiotechnology an overweight rating, with R&D advancement, production capacity expansion, and promising growth in the peptide field.

According to AI News, China International Finance Securities issued a research report on October 31, saying that it gave shengnuobiotechnology (688117.SH, latest price: 30.64 yuan) an overweight rating.

Reasons for rating mainly include:

1) Focus on peptide APIs and preparations, with 8 core technologies supporting R&D advancement;

2) Capacity expansion ensures revenue growth, and the approaching patent period is expected to further open up the peptide market space.